0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD34

CD34

CD34 Molecule Information

Name:Hematopoietic progenitor cell antigen CD34
Target Synonym:CD34
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

CD34 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD4-H5255 Human Human CD34 Protein, Fc Tag
CD4-H5255-structure
CD4-H5255-sds

CD34 Molecule Synonym Name

CD34,RP11-328D5.2

CD34 Molecule Background

CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

CD34 References

CD34 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anti-CD34 mab-sirolimus (OrbusNeich) Approved OrbusNeich Coronary restenosis Details

CD34 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Stem cell therapeutics (ExCellThera) ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 Phase Ⅱ ExCellThera hematological malignancies, Multiple myeloma (MM), Acute myeloid Leukemia (AML) Details
Autologous stem cell therapy (Shire) Phase Ⅲ Shire, Caladrius Biosciences Peripheral vascular disorders, Myocardia ischemia Details
Dilanubicel (Nohla Therapeutics) NLA-101,NLA 101 Phase Ⅲ Fred Hutchinson Cancer Research Center, Nohla Therapeutics Neutropenia, Acute radiation syndrome, Graft versus host disease, Infectious disease, Haematological disorders Details
Autologous peripheral blood stem cell therapy (CellProthera) Phase Ⅱ CellProthera Myocardial infarction (MI) Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) Phase Ⅰ University Health Network Fabry disease Details
Elivaldogene tavalentivec (bluebird bio) Phase Ⅲ INSERM, bluebird bio Adrenoleucodystrophy Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) Phase Ⅱ UCLA Biomedical Adenosine deaminase deficiency Details
MB-107 MB-107; IND-14570 Phase Ⅱ St. Jude Children's Research Hospital, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Mustang Bio Immunodeficiency disorders Details
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) Phase Ⅱ Genenta Science Glioblastoma multiforme, Multiple myeloma (MM) Details
CLBS-12 CLBS-12 Phase Ⅱ Caladrius Biosciences Peripheral ischaemia Details
γ-globin gene therapy (CSL Behring) CSL-200,CSL 200 Phase Ⅰ CSL Behring Sickle cell disease Details
CD34-mdr1 gene therapy (University of Michigan) AM12M1-MDR1 Phase Ⅱ University of Michigan Cancer Details
GSK-2696277 GSK-2696277,GSK 2696277,GSK2696277 Phase Ⅱ Fondazione Telethon, Ospedale San Raffaele, GlaxoSmithKline Thelassemia Details
RTX-134 RTX-134 Preclinical Rubius Therapeutics Phenylketonuria (PKU) Details
shRNA-modified CD34 cell therapy (Kanglin Biotech) Phase Ⅰ Kanglin Biotech HIV infection Details
CD34 stem cell therapy (LA Childrens Hospital) Phase Ⅰ Children's Hospital of Los Angeles HIV infection Details
Alecmestencel-T (Apceth) Phase Ⅱ Apceth Gastrointestinal cancer, Peripheral arterial occlusive disorders Details

This web search service is supported by Google Inc.

totop